Skip to main content
SpringerLink
Log in

Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics

Useful Aid to Prescribing?

Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Many antipsychotics, including perphenazine, zuclopenthixol, thioridazine, haloperidol and risperidone, are metabolised to a significant extent by the polymorphic cytochrome P450 (CYP) 2D6, which shows large interindividual variation in activity. Significant relationships between CYP2D6 genotype and steady-state concentrations have been reported for perphenazine, zuclopenthixol, risperidone and haloperidol when used in monotherapy. Other CYPs, especially CYP1A2 and CYP3A4, also contribute to the interindividual variability in the kinetics of antipsychotics and the occurrence of drug interactions. For many antipsychotics, the role of the different CYPs at therapeutic drug concentrations remains to be clarified. Some studies have suggested that poor metabolisers for CYP2D6 would be more prone to oversedation and possibly parkinsonism during treatment with classical antipsychotics, whereas other, mostly retrospective, studies have been negative or inconclusive. For the newer antipsychotics, such data are lacking. Whether phenotyping or genotyping for CYP2D6 or other CYPs can be used to predict an optimal dose range has not been studied so far. Genotyping or phenotyping can today be recommended as a complement to plasma concentration determination when aberrant metabolic capacity (poor or ultrarapid) of CYP2D6 substrates is suspected. The current rapid developments in molecular genetic methodology and pharmacogenetic knowledge can in the near future be expected to provide new tools for prediction of the activity of the various drugmetabolising enzymes. Further prospective clinical studies in well-defined patient populations and with adequate evaluation of therapeutic and adverse effects are required to establish the potential of pharmacogenetic testing in clinical psychiatry.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Fig. 3
Table II

References

  1. Someya T, Inaba T, Tyndale RF, et al. Conversion of bromperidol to reduced bromperidol in human liver. Neuropsychopharmacology 1991; 5: 177–82

    PubMed  CAS  Google Scholar 

  2. Sato S, Someya T, Shioiri O, et al. Involvement of CYP3A4 in the metabolism of bromperidol in vitro. Pharmacol Toxicol 2000; 86: 145–8

    Article  PubMed  CAS  Google Scholar 

  3. Suzuki A, Otani K, Mihara K, et al. Effects of various factors including CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolite. Psychopharmacology 1998; 135: 333–7

    Article  PubMed  CAS  Google Scholar 

  4. Yoshii K, Kobayashi K, Tsumuji M, et al. Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci 2000; 67: 175–84

    Article  PubMed  CAS  Google Scholar 

  5. Fischer V, Vogels B, Maurer G, et al. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther 1992; 260: 1355–60

    PubMed  CAS  Google Scholar 

  6. Linnet K, Olesen OV. Metabolism of clozapine by cDNA expressed human cytochrome P450 enzymes. Drug Metab Dispos 1997; 25: 1379–82

    PubMed  CAS  Google Scholar 

  7. Pirmohamed M, Williams D, Madden S, et al. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995; 272: 984–90

    PubMed  CAS  Google Scholar 

  8. Eiermann B, Engel G, Johansson I, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997; 44: 439–46

    Article  PubMed  CAS  Google Scholar 

  9. Dahl ML, Llerena A, Bondesson U, et al. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol 1994; 37: 71–4

    Article  PubMed  CAS  Google Scholar 

  10. Llerena A, Alm C, Dahl ML, et al. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 1992; 14: 92–7

    Article  PubMed  CAS  Google Scholar 

  11. Llerena A, Dahl ML, Ekqvist B, et al. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 1992; 14: 261–4

    Article  PubMed  CAS  Google Scholar 

  12. Nyberg S, Farde L, Halldin C, et al. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995; 152: 173–8

    PubMed  CAS  Google Scholar 

  13. Suzuki A, Otani K, Mihara K, et al. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics 1997; 7: 415–8

    Article  PubMed  CAS  Google Scholar 

  14. Mihara K, Suzuki A, Kondo T, et al. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Clin Pharmacol Ther 1999; 65: 291–4

    Article  PubMed  CAS  Google Scholar 

  15. Someya T, Suzuki Y, Shimoda K, et al. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population. Psychiatry Clin Neurosci 1999; 53: 593–7

    Article  PubMed  CAS  Google Scholar 

  16. Shimoda K, Morita S, Someya T, et al. CYP2D6* 10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients. Ther Drug Monit 2000; 122: 392–6

    Article  Google Scholar 

  17. Roh HK, Chung JY, Oh DY, et al. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high, doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol 2001; 52: 265–71

    Article  PubMed  CAS  Google Scholar 

  18. Pan L, Vander Stichele R, Rosseel MT, et al. Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients. Ther Drug Monit 1999; 21: 489–97

    Article  PubMed  CAS  Google Scholar 

  19. Kassahun K, Mattiuz E, Nyhart Jr E, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 1997; 25: 81–93

    PubMed  CAS  Google Scholar 

  20. Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet 2000; 38: 393–414

    Article  PubMed  CAS  Google Scholar 

  21. Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996; 276: 658–66

    PubMed  CAS  Google Scholar 

  22. Hägg S, Spigset O, Lakso HÅ, et al. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur J Clin Pharmacol 2001; 57: 493–7

    Article  PubMed  Google Scholar 

  23. Dahl-Puustinen ML, Liden A, Alm C, et al. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 1989; 46: 78–81

    Article  PubMed  CAS  Google Scholar 

  24. Jerling M, Dahl ML, Åberg-Wistedt A, et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 1996; 59: 423–8

    Article  PubMed  CAS  Google Scholar 

  25. Linnet K, Wiborg O. Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin Pharmacol Ther 1996; 60: 41–7

    Article  PubMed  CAS  Google Scholar 

  26. Olesen OV, Linnet K. Identification of the human cytochrome P450 isoforms mediating in vitro dealkylation of perphenazine. Br J Clin Pharmacol 2000; 50: 563–71

    Article  PubMed  CAS  Google Scholar 

  27. Scordo MG, Spina E, Facciola G, et al. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 1999; 147: 300–5

    Article  CAS  Google Scholar 

  28. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 1999; 359: 147–51

    Article  PubMed  CAS  Google Scholar 

  29. Huang ML, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54: 257–68

    Article  PubMed  CAS  Google Scholar 

  30. Nyberg S, Dahl ML, Halldin C. A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. Psychopharmacology (Berl) 1995; 119: 345–8

    Article  CAS  Google Scholar 

  31. Olesen OV, Licht RW, Thomsen E, et al. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 1998; 20: 380–4

    Article  PubMed  CAS  Google Scholar 

  32. Roh HK, Kim CE, Chung WG, et al. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol 2001; 57: 671–5

    Article  PubMed  CAS  Google Scholar 

  33. Yasui-Furukori N, Hidestrand M, Spina E, et al. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 2001; 29(10): 1263–8

    PubMed  CAS  Google Scholar 

  34. von Bahr C, Movin G, Nordin C, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1991; 49: 234–40

    Article  Google Scholar 

  35. Eap CB, Guentert TW, Schaublin Loidl M, et al. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clin Pharmacol Ther 1996; 59: 322–31

    Article  PubMed  CAS  Google Scholar 

  36. Shiraga T, Kaneko H, Iwasaki K, et al. Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica 1999; 29: 217–29

    Article  PubMed  CAS  Google Scholar 

  37. Dahl ML, Ekqvist B, Widen J, et al. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand 1991; 84: 99–102

    Article  PubMed  CAS  Google Scholar 

  38. Linnet K, Wiborg O. Influence of CYP2D6 genetic polymorphism on ratios of steady-state serum concentrations to dose of the neuroleptic zuclopenthixol. Ther Drug Monit 1996; 18: 629–34

    Article  PubMed  CAS  Google Scholar 

  39. Jaanson P, Marandi T, Kiivet R-A, et al. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side-effects and CYP2D6 genotype. Psychopharmacology 2002. In press

  40. Hiemke C, Weigmann H, Härtter S, et al. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994; 14: 279–81

    Article  PubMed  CAS  Google Scholar 

  41. Jerling M, Lindstrom L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16: 368–74

    Article  PubMed  CAS  Google Scholar 

  42. Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 38: 471–3

    Article  PubMed  CAS  Google Scholar 

  43. Özdemir V, Kalow W, Posner P, et al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite norclozapine steady-state concentrations in patients with schizophrenia. J Clin Psychopharmacol 2001; 21: 398–407

    Article  PubMed  Google Scholar 

  44. Shimoda K, Someya T, Morita S, et al. Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients. Ther Drug Monit 1999; 21: 293–6

    Article  PubMed  CAS  Google Scholar 

  45. Skogh E, Reis M, Dahl M-L, et al. Therapeutic drug monitoring data on olanzapine and its N-desmethyl metabolite in the naturalistic clinical setting. Ther Drug Monit, 2002. In press

  46. Mäenpää J, Wrighton S, Bergstrom R, et al. Pharmacokinetic (PK) and pharmacodynamic (PD) interactions between fluvoxamine and olanzapine [abstract]. Clin Pharmacol Ther 1997; 61: 225

    Google Scholar 

  47. Markowitz JS, DeVane CL. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration. J Clin Psychopharmacol 1999; 19: 289–91

    Article  PubMed  CAS  Google Scholar 

  48. Carrillo JA, Ramos SI, Herraiz AG, et al. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J Clin Psychopharmacol 1999; 19: 494–9

    Article  PubMed  CAS  Google Scholar 

  49. Stormer E, Brockmoller J, Roots I, et al. Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl) 2000; 151: 312–20

    Article  CAS  Google Scholar 

  50. Furukori H, Kondo T, Yasui N, et al. Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. Psychopharmacology (Berl) 1999; 145: 189–92

    Article  CAS  Google Scholar 

  51. Raaska K, Neuvonen PJ. Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol 1998; 54: 167–70

    Article  PubMed  CAS  Google Scholar 

  52. Hägg S, Spigset O, Mjörndal T, et al. Absence of interaction between erythromycin and a single dose of clozapine. Eur J Clin Pharmacol 1999; 55: 221–6

    Article  PubMed  Google Scholar 

  53. Vandel S, Netillard C, Perault MC, et al. Plasma levels of clozapine and desmethylclozapine are unaffected by concomitant ingestion of grapefruit juice. Eur J Clin Pharmacol 2000; 56: 347–8

    Article  PubMed  CAS  Google Scholar 

  54. Yasui N, Kondo T, Otani K, et al. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism. J Clin Psychopharmacol 1999; 19: 149–54

    Article  PubMed  CAS  Google Scholar 

  55. Fang J, Baker GB, Silverstone PH, et al. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell Mol Neurobiol 1997; 17: 227–33

    Article  PubMed  CAS  Google Scholar 

  56. Pan L, Belpaire FM. In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol. Eur J Clin Pharmacol 1999; 55: 599–604

    Article  PubMed  CAS  Google Scholar 

  57. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001; 40: 509–22

    Article  PubMed  CAS  Google Scholar 

  58. Prakash C, Kamel A, Cui D, et al. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 2000; 49 Suppl. I: S35–42

    Google Scholar 

  59. Miceli JJ, Anziano RJ, Robarge L, et al. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol 2000; 49 Suppl. I: S65–70

    Google Scholar 

  60. Dahl ML, Sjöqvist F. Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. Ther Drag Monit 2000; 22: 114–7

    Article  CAS  Google Scholar 

  61. Streetman DS, Bertino Jr JS, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000; 10: 187–216

    Article  PubMed  CAS  Google Scholar 

  62. Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584–6

    Article  PubMed  CAS  Google Scholar 

  63. Tucker GT, Silas JH, Iyun AO, et al. Polymorphic hydroxylation of debrisoquine [letter]. Lancet 1997; 2: 718

    Google Scholar 

  64. Eichelbaum M, Spannbrucker N, Steincke B, et al. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16: 183–7

    Article  PubMed  CAS  Google Scholar 

  65. Evans DA, Mahgoub A, Sloan TP, et al. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980; 17: 102–5

    Article  PubMed  CAS  Google Scholar 

  66. Alvan G, Bechtel P, Iselius L, et al. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39: 533–7

    Article  PubMed  CAS  Google Scholar 

  67. Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 1992; 51: 388–97

    Article  PubMed  CAS  Google Scholar 

  68. Bertilsson L, Dahl M-L. Polymorphic drag oxidation: relevance to the treatment of psychiatric disorders. CNS Drags 1996; 5: 200–23

    Article  CAS  Google Scholar 

  69. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 1993; 90: 11825–9

    Article  PubMed  CAS  Google Scholar 

  70. Dahl ML, Johansson I, Bertilsson L, et al. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274: 516–20

    PubMed  CAS  Google Scholar 

  71. Syvälahti EKG, Lindberg R, Kallio J, et al. Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 1986; 22: 89–92

    PubMed  Google Scholar 

  72. Spina E, Martines C, Caputi AP, et al. Debrisoquine oxidation phenotype during neuroleptic monotherapy. Eur J Clin Pharmacol 1991; 41: 467–70

    Article  PubMed  CAS  Google Scholar 

  73. Llerena A, Herraiz AG, Cobaleda J, et al. Debrisoquine and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin Pharmacol Ther 1993; 54: 606–11

    Article  PubMed  CAS  Google Scholar 

  74. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Criteria for inclusion, and nomenclature files [online]. Available from: http://www.imm.ki.se/CYPalleles/

  75. Ingelman-Sundberg M, Oscarsson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20: 342–9

    Article  PubMed  CAS  Google Scholar 

  76. Johansson I, Oscarson M, Yue QY, et al. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46: 452–9

    PubMed  CAS  Google Scholar 

  77. Sachse C, Brockmöller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284–95

    PubMed  CAS  Google Scholar 

  78. Griese EU, Zanger UM, Brudermanns U, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8: 15–26

    Article  PubMed  CAS  Google Scholar 

  79. Dahl ML, Johansson I, Palmertz MP, et al. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992; 51: 12–7

    Article  PubMed  CAS  Google Scholar 

  80. Broly F, Meyer UA. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. Pharmacogenetics 1993; 3: 123–30

    Article  PubMed  CAS  Google Scholar 

  81. Raimundo S, Fischer J, Eichelbaum M, et al. Elucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drag oxidation by CYP2D6. Pharmacogenetics 2000; 10: 577–81

    Article  PubMed  CAS  Google Scholar 

  82. Agundez JA, Ledesma MC, Ladero JM, et al. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995; 57: 265–9

    Article  PubMed  CAS  Google Scholar 

  83. Bernal M-L, Sinues B, Johansson I, et al. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. Pharmacogenetics 1999; 9: 657–60

    Article  PubMed  CAS  Google Scholar 

  84. Aklillu E, Persson I, Bertilsson L, et al. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278: 441–6

    PubMed  CAS  Google Scholar 

  85. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38: 402–8

    Article  PubMed  CAS  Google Scholar 

  86. Sohn DR, Shin SG, Park CW, et al. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br J Clin Pharmacol 1991; 32: 504–7

    Article  PubMed  CAS  Google Scholar 

  87. Masimirembwa C, Persson I, Bertilsson L, et al. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996; 42: 713–9

    Article  PubMed  CAS  Google Scholar 

  88. Wrighton SA, Stevens JC, Becker GW, et al. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993; 306: 240–5

    Article  PubMed  CAS  Google Scholar 

  89. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33: 1743–52

    Article  PubMed  CAS  Google Scholar 

  90. Jurima M, Inaba T, Kadar D, et al. Genetic polymorphism of mephenytoin p- (4)-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 1985; 19: 483–7

    Article  PubMed  CAS  Google Scholar 

  91. Sohn DR, Kusaka M, Ishizaki T, et al. Incidence of Smephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics [see comments]. Clin Pharmacol Ther 1992; 52: 160–9

    Article  PubMed  CAS  Google Scholar 

  92. Masimirembwa C, Bertilsson L, Johansson I, et al. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995; 57: 656–61

    Article  PubMed  CAS  Google Scholar 

  93. Persson I, Aklillu E, Rodrigues F, et al. S-Mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 1996; 6: 521–6

    Article  PubMed  CAS  Google Scholar 

  94. Herrlin K, Massele AY, Jande M, et al. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther 1998; 64: 391–401

    Article  PubMed  CAS  Google Scholar 

  95. Chang M, Dahl ML, Tybring G, et al. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995; 5: 358–63

    Article  PubMed  CAS  Google Scholar 

  96. de Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of Smephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419–22

    PubMed  Google Scholar 

  97. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997; 7: 59–64

    Article  PubMed  CAS  Google Scholar 

  98. de Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594–8

    PubMed  Google Scholar 

  99. Roh HK, Dahl ML, Tybring G, et al. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996; 6: 547–51

    Article  PubMed  CAS  Google Scholar 

  100. Miners JO, Birkett DJ. Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Methods Enzymol 1996; 272: 139–45

    Article  PubMed  CAS  Google Scholar 

  101. Aynacioglu AS, Brockmöller J, Bauer S, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48: 409–15

    Article  PubMed  CAS  Google Scholar 

  102. Morin S, Loriot MA, Poirier JM, et al. Is diclofenac a valuable CYP2C9 probe in humans? Eur J Clin Pharmacol 2001; 56: 793–7

    Article  PubMed  CAS  Google Scholar 

  103. Yasar Ü, Forslund-Bergengren C, Tybring G, et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002; 71: 89–98

    Article  PubMed  CAS  Google Scholar 

  104. Rettie AE, Wienkers LC, Gonzalez FJ, et al. Impaired (S) warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4: 39–42

    Article  PubMed  CAS  Google Scholar 

  105. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6: 341–9

    Article  PubMed  CAS  Google Scholar 

  106. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525–38

    Article  PubMed  CAS  Google Scholar 

  107. Yasar Ü, Eliasson E, Dahl ML, et al. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population [published erratum appears in Biochem Biophys Res Commun 1999 Apr; 258: 227]. Biochem Biophys Res Commun 1999; 254: 628–31

    Article  PubMed  CAS  Google Scholar 

  108. Scordo MG, Aklillu E, Yasar Ü, et al. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001; 52: 447–50

    Article  PubMed  CAS  Google Scholar 

  109. Relling MV, Lin JS, Ayers GD, et al. Racial and gender differences in N-acetyltransferase, xanthine oxidase and CYP1A2 activity. Clin Pharmacol Ther 1994; 55: 402–11

    Article  Google Scholar 

  110. Kalow W, Tang BK. Use of caffeine metabolic ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991; 50: 508–19

    Article  PubMed  CAS  Google Scholar 

  111. Bologa M, Tang B, Klein J, et al. Pregnancy-induced changes in drug metabolism in epileptic women. J Pharmacol Exp Ther 1991; 257: 735–40

    PubMed  CAS  Google Scholar 

  112. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993; 53: 503–14

    Article  PubMed  CAS  Google Scholar 

  113. Nakajima M, Yokoi T, Mizutani M, et al. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 1999; 125: 803–8

    Article  PubMed  CAS  Google Scholar 

  114. Sachse C, Brockmöller J, Bauer S, et al. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47: 445–9

    Article  PubMed  CAS  Google Scholar 

  115. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414–23

    PubMed  CAS  Google Scholar 

  116. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 171–84

    Article  PubMed  CAS  Google Scholar 

  117. Sata F, Sapone A, Elizondo G, et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000; 67: 48–56

    Article  PubMed  CAS  Google Scholar 

  118. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383–91

    Article  PubMed  CAS  Google Scholar 

  119. Chakraborty BS, Hubbard JW, Hawes EM, et al. Interconversion between haloperidol and reduced haloperidol in healthy volunteers. Eur J Clin Pharmacol 1989; 37: 45–8

    PubMed  CAS  Google Scholar 

  120. Dahl SG. Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. Ther Drug Monit 1982; 4: 33–40

    Article  PubMed  CAS  Google Scholar 

  121. Hale P, Poklis A. Thioridazine cardiotoxicity. J Toxicol Clin Toxicol 1996; 34: 127–30

    Article  PubMed  CAS  Google Scholar 

  122. Bagli M, Höflich G, Rao ML, et al. Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects. Int J Clin Pharmacol Ther 1995; 33: 646–52

    PubMed  CAS  Google Scholar 

  123. Mannens G, Huang ML, Meuldermans W, et al. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 1993; 21: 1134–41

    PubMed  CAS  Google Scholar 

  124. Bork JA, Rogers T, Wedlund PJ, et al. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 1999; 60: 469–76

    Article  PubMed  CAS  Google Scholar 

  125. Güsey C, Aamo T, Spigset O. Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer. J Clin Psychiatry 2000; 61: 600–1

    Article  Google Scholar 

  126. Brøsen K, Skjelbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211–4

    Article  PubMed  Google Scholar 

  127. Noda K, Suzuki A, Okui M, et al. Pharmacokinetics and metabolism of 2-chloro-11-(2-dimethylaminoethoxy)- dibenzo-[b,f]thiepine (zotepine) in rat, mouse, dog and man. Arzneimittelforschung 1979; 29: 1595–600

    PubMed  CAS  Google Scholar 

  128. Lane HY, Hu OYP, Jann MW, et al. Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. Psychiatry Res 1997; 69: 105–11

    Article  PubMed  CAS  Google Scholar 

  129. Pollock BG, Mulsant BH, Sweet RA, et al. Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull 1995; 31: 327–31

    PubMed  CAS  Google Scholar 

  130. Aitchison KJ, Munro J, Wright P, et al. Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation. Br J Clin Pharmacol 1999; 48: 388–94

    Article  PubMed  CAS  Google Scholar 

  131. Sachse C, Schmider J, Kanitz P, et al. Frequency of CYP2D6 genotypes in schizophrenic patients and relation to antipsychotic therapy [abstract]. Abstracts of the joint meeting of VII World Conference on Clinical Pharmacology and Therapeutics IUPHAR - Division of Clinical Pharmacology & 4th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT); 2000 July 15–20; Florence. Br J Clin Pharmacol 2000, 190

  132. Spina E, Ancione M, Di Rosa AE, et al. Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. Eur J Clin Pharmacol 1992; 42: 347–8

    Article  PubMed  CAS  Google Scholar 

  133. Spina E, Sturiale V, Valvo S, et al. Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions. Acta Psychiatr Scand 1992; 86: 364–6

    Article  PubMed  CAS  Google Scholar 

  134. Meyer JW, Woggon B, Baumann P, et al. Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur J Clin Pharmacol 1990; 39: 613–4

    Article  PubMed  CAS  Google Scholar 

  135. Arthur H, Dahl ML, Siwers B, et al. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol 1995; 15: 211–6

    Article  PubMed  CAS  Google Scholar 

  136. Andreassen OA, MacEwan T, Gulbrandsen AK, et al. Nonfunctional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology (Berl) 1997; 131: 174–9

    Article  CAS  Google Scholar 

  137. Vandel P, Haffen E, Vandel S, et al. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes. Eur J Clin Pharmacol 1999; 55: 659–65

    Article  PubMed  CAS  Google Scholar 

  138. Scordo MG, Spina E, Romeo P, et al. CYP2D6 genotype and antipsychotic-induced extrapyramidal side-effects in schizophrenic patients. Eur J Clin Pharmacol 2000; 56: 679–83

    Article  PubMed  CAS  Google Scholar 

  139. Kapitany T, Meszaros K, Lenzinger E, et al. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 1998; 32: 101–6

    Article  PubMed  CAS  Google Scholar 

  140. Ohmori O, Kojima H, Shinkai T, et al. Genetic association analysis between CYP2D6*2 allele and tardive dyskinesia in schizophrenic patients. Psychiatry Res 1999; 87: 239–44

    Article  PubMed  CAS  Google Scholar 

  141. Armstrong M, Daly AK, Blennerhassett R, et al. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry 1997; 170: 23–6

    Article  PubMed  CAS  Google Scholar 

  142. Hamelin BA, Dorson PG, Pabis D, et al. CYP2D6 mutations and therapeutic outcome in schizophrenic patients. Pharmacotherapy 1999; 19: 1057–63

    Article  PubMed  CAS  Google Scholar 

  143. Otani K, Aoshima T. Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit 2000; 22: 118–21

    Article  PubMed  CAS  Google Scholar 

  144. Chou WH, Yan F-X, de Leon J, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 2000; 20: 246–51

    Article  PubMed  CAS  Google Scholar 

  145. Basile VS, Ozdemir V, Masellis M, et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 2000; 5: 410–7

    Article  PubMed  CAS  Google Scholar 

  146. Schulze TG, Schumacher J, Muller DJ, et al. Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001; 105: 498–501

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Grants from the Swedish Medical Research Council (3902), the Swedish Society of Medicine, European Union (INCO-Copernicus ERBIC15CT980340), and the Karolinska Institute supported the studies performed by the author and reviewed in this paper.

Author information

Authors and Affiliations

  1. Department of Medical Sciences, Clinical Pharmacology, Uppsala University Hospital, Uppsala, SE-751 85, Sweden

    Marja-Liisa Dahl

Authors
  1. Marja-Liisa Dahl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marja-Liisa Dahl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dahl, ML. Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics. Clin Pharmacokinet 41, 453–470 (2002). https://doi.org/10.2165/00003088-200241070-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200241070-00001

Keywords

Search

Navigation